SCHEDULE: Panacea Venture Affiliates Maintain Significant Stake in CASI Pharmaceuticals
Beneficial Ownership Update
Panacea Venture Healthcare Fund II, L.P. and its related entities, including James Huang, reported continued beneficial ownership of 13.8% of CASI Pharmaceuticals, Inc.'s Ordinary Shares.
Summary
- Panacea Venture Healthcare Fund II, L.P., Panacea Venture Healthcare Fund II GP Company, Ltd., and Panacea Innovation Limited collectively beneficially own 2,050,000 Ordinary Shares of CASI Pharmaceuticals, Inc., representing 13.2% of the class.
- James Huang, through his sole ownership of Panacea Innovation Limited and direct options, beneficially owns an aggregate of 2,161,571 Ordinary Shares, representing 13.8% of the class.
- The beneficial ownership is based on 15,506,348 Ordinary Shares outstanding as of June 20, 2025.
- The shares were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of CASI Pharmaceuticals, Inc.
Sentiment
Score: 6
Explanation: The filing is a routine disclosure of a significant, stable beneficial ownership stake, indicating continued investor confidence without suggesting any immediate positive or negative operational changes.
Positives
- Continued significant beneficial ownership by Panacea Venture and James Huang indicates ongoing investor confidence in CASI Pharmaceuticals, Inc.
- The filing explicitly states that the shares are not held for the purpose of changing or influencing the control of the issuer, suggesting stability in corporate governance.
Future Outlook
NA
Industry Context
This filing is a routine disclosure of beneficial ownership by a significant investor in a pharmaceutical company, common in the biotech and healthcare sectors where venture funds often take substantial equity positions.
Stakeholder Impact
- Shareholders are informed of the continued significant ownership stake held by Panacea Venture and James Huang, providing transparency regarding the company's ownership structure.
Key Dates
| Date | Description |
|---|---|
| 2025-06-20 | Date as of which the number of outstanding Ordinary Shares (15,506,348) was determined for beneficial ownership calculation. |
| 2025-06-30 | Date of event which required the filing of this statement. |
| 2025-07-23 | Date of signature for the Schedule 13G filing. |
Keywords
CASI Pharmaceuticals, Panacea Venture, Beneficial Ownership, Schedule 13G, Ordinary Shares, Investment, Healthcare Fund, James Huang
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.